PTC Therapeutics | PTCT - Current Liabilities


PTC Therapeutics reported $968.43M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Cytokinetics USD 202.45M 60.31M Dec/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Ironwood Pharmaceuticals USD 242.5M 9.98M Sep/2025
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
TG Therapeutics USD 153.76M 3.05M Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xencor USD 95.91M 9.42M Dec/2025